Drug Development is a challenging process. It needs profound basic research, translating scientific results into products and moving them towards the market.
Making things more challenging deal structuring is also a b2b business, which means selling products to the pharma industry that completes the product development and brings therapeutics to patients.
How does structuring deals with the pharma industry really work to sign one of those multi-billion dollar contracts?
Sascha Bucher is a Venture Capital expert with tremendous experience in deal structuring with the pharmaceutical industry.
In his career at renowned venture funds and companies like Roivant Sciences, Roche, or UBS, he completed transactions worth more than 10 billion dollars.
To give life science entrepreneurs access to the expertise, network, and funding, he and his team are in the process of founding Forty51 Ventures - a novel venture fund dedicated to closing the Life Science Valley of Death in Central Europe.
Join our conversation and learn more about how to negotiate with the pharmaceutical industry.
Gain more insights into VCs' daily business life with a particular focus on building relationships with BD, R&D, and C-suite executives in the industry.
Link to the Video of the Recording:
YouTube
Speaker:
Astrid Woollard
Christian Soschner
Sascha Bucher
Organizations:
CS Life Science Invest
Forty51 Ventures
Scytale Ventures
Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g
Support the show (https://www.lifescienceget2gether.com/registration-membersclub/)
The LSG2G Partners
Experts in Life Science
#34: Deal Structuring With the Pharma Industry - From the Investors Perspective